Our Science

OROX BioSciences harnesses the beneficial effects of inhibiting sEH selectively or in concert with secondary targets to gain efficacy and bring about resolution to disease states such as fibrosis.

foundation-icon
Our Team

Experts from the academic, clinical, and biopharma settings

approch-icon
Our Science

Combating fibrosis by altering lipid metabolism

pipline-icon
Pipeline

Rapid and efficient progression

About Us

OROX BioSciences, Inc. is an early stage biotechnology start-up dedicated to efficient discovery and development of innovative small molecule drugs to address unmet medical needs for fibrotic diseases since 2017.

Our core technology is around inhibition of soluble epoxide hydrolase (sEH) to ameliorate disease states. The core competence of our team is in understanding lipid metabolism and its interphase with disease states.

Therapeutic Programs

OROX BioSciences is dedicated to discovering therapies for various forms of fibrosis

lung
Idiopathic Pulmonary Fibrosis

IPF is a progressive, agonizing, debilitating and ultimately fatal disease that affects <200,000 individuals in the United States and approximately 5 million individuals worldwide.  IPF diminishes the patient’s ability to breathe over a period of time.  Median survival from the time of diagnosis is 3 years, which is worse than many cancers.

Star
To be announced

Fibrosis results from excess deposition of fibrous connective tissue by fibroblasts during the repair process which results in continuous scarring and loss of normal organ elasticity and function.

 

 

 

Star
To be announced

Fibrosis results from excess deposition of fibrous connective tissue by fibroblasts during the repair process which results in continuous scarring and loss of normal organ elasticity and function.

 

 

 

GET IN TOUCH

Office

12636 High Bluff Drive, Suite 400, San Diego, CA 92130, USA